Back
LEXX
HealthcareLexaria Bioscience Corp.
Next Earnings: Q4 2025
Friday, January 9, 2026
Loading...
LEXX EPS History & Predictions
Actual
Consensus
Wall Street
$-0.17consensus
GPT-5.2
$-0.17▲
Claude-opus
$-0.13▲
Gemini 3 Pro
$-0.13▲
GPT-5.2
$-0.13▲
Grok-4
$-0.13▲
Q4 2025 Predictions
AI analyst forecasts for the upcoming earnings release. Click a model to see its reasoning.
GPT-5.2
openrouterEPS
$-0.17
Revenue
$0.00B
Conf.
42%Click for details →
Claude-opus
openrouterEPS
$-0.13
Revenue
$0.00B
Conf.
65%Click for details →
Gemini 3 Pro
openrouterEPS
$-0.13
Revenue
$0.00B
Conf.
85%Click for details →
GPT-5.2
openrouterEPS
$-0.13
Revenue
$0.00B
Conf.
42%Click for details →
Grok-4
openrouterEPS
$-0.13
Revenue
$0.00B
Conf.
75%Click for details →
Predictions Comparison
AI model predictions compared to Wall Street consensus
| Model | EPS Estimate | Revenue Estimate | vs Consensus | Confidence | |
|---|---|---|---|---|---|
GPT-5.2openrouter | $-0.17 | $0.00B | +0.0% | 42% | |
Claude-opusopenrouter | $-0.13 | $0.00B | -23.5% | 65% | |
Gemini 3 Proopenrouter | $-0.13 | $0.00B | -23.5% | 85% | |
GPT-5.2openrouter | $-0.13 | $0.00B | -23.5% | 42% | |
Grok-4openrouter | $-0.13 | $0.00B | -23.5% | 75% | |
| Wall Street Consensus | $-0.17 | $0.00B | — | — |
Wall Street Consensus
Compare AI predictions against Wall Street analyst consensus
Consensus EPS
$-0.15
Last Reported EPS
$-0.21
Last Surprise
-40.00%
Report Date
7/14/2025
Quarterly Earnings Surprise Amount
Historical performance vs Wall Street consensus
| Fiscal Quarter End | Date Reported | Earnings Per Share* | Consensus EPS* Forecast | % Surprise |
|---|---|---|---|---|
| Q3 2025 | 7/14/2025 | -0.21 | — | -40.00 |
| Q2 2025 | 4/14/2025 | -0.15 | — | 6.25 |
| Q1 2025 | 1/10/2025 | -0.16 | — | -33.33 |
| Q4 2024 | 11/26/2024 | -0.17 | — | -54.55 |
* EPS values are adjusted for stock splits
Financial Statements
Historical data with AI projections for Q4 2025
All values in Millions (USD) unless otherwise noted
AI Projections | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Line Item | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | GPT-5.2Q4 2025 | Claude-opusQ4 2025 | Gemini 3 ProQ1 2026 | GPT-5.2Q4 2025 | Grok-4Q4 2025 |
| Revenue | |||||||||
| Revenue | 0.084 | 0.184 | 0.174 | 0.174 | 0.176+1.1% | 0.170-2.3% | 0.175+0.6% | 0.180+3.4% | 0.175+0.6% |
| Cost Of Revenue | 0 | 0.003 | 0 | 0 | 0 | 0 | 0 | 0.002 | 0 |
| Cost & Gross Profit | |||||||||
| Gross Profit | 0.084 | 0.181 | 0.174 | 0.174 | 0.176+1.1% | 0.170-2.3% | 0.175+0.6% | 0.178+2.6% | 0.175+0.6% |
| Cost And Expenses | 2.29 | 2.87 | 2.93 | 3.92 | 3.49-11.1% | 3.05-22.3% | 2.55-35.0% | 2.85-27.3% | 3.70-5.7% |
| Operating Expenses | |||||||||
| Research And Development Expenses | 0.967 | 1.95 | 1.69 | 2.72 | 2.25-17.2% | 1.90-30.1% | 1.40-48.5% | 1.75-35.6% | 2.50-8.0% |
| General And Administrative Expenses | 1.32 | 0.919 | 1.24 | 1.21 | 1.24+2.7% | 1.15-4.7% | 1.15-4.7% | 1.10-8.9% | 1.20-0.6% |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 1.32 | 0.919 | 1.24 | 1.21 | 1.24+2.7% | 1.15-4.7% | 1.15-4.7% | 1.10-8.9% | 1.20-0.6% |
| Other Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 2.29 | 2.87 | 2.93 | 3.92 | 3.49-11.1% | 3.05-22.3% | 2.55-35.0% | 2.85-27.4% | 3.70-5.7% |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net | 0.016 | -0.013 | 0.034 | -0.040 | -0.006+85.1% | 0.015+137.3% | 200.00+100.5% | -0.030+25.3% | 200.00+100.5% |
| Income Tax Expense | 0 | 0 | 0.004 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | |||||||||
| Net Interest Income | 0.007 | 11.00 | 0 | 190.00 | 0.001+426.3% | 0.015 | 200.00+5.3% | 0.001+426.3% | 200.00+5.3% |
| Interest Income | 0.007 | 11.00 | 0 | 190.00 | 0.001+426.3% | 0.015 | 200.00+5.3% | 0.001+426.3% | 200.00+5.3% |
| Non Operating Income Excluding Interest | 0.015 | 0 | 0 | 0 | -0.007 | 0 | 0 | 0 | 0 |
| Other Adjustments To Net Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income & EPS | |||||||||
| Operating Income | -2.20 | -2.69 | -2.75 | -3.75 | -3.31+11.6% | -2.88+23.2% | -2.38+36.7% | -2.67+28.8% | -3.52+6.0% |
| Income Before Tax | -2.19 | -2.70 | -2.71 | -3.79 | -3.32+12.4% | -2.87+24.4% | -2.37+37.4% | -2.70+28.8% | -3.52+7.0% |
| Net Income From Continuing Operations | -2.19 | -2.70 | -2.72 | -3.79 | -3.32+12.4% | -2.87+24.4% | -2.37+37.4% | -2.70+28.8% | -3.52+7.0% |
| Net Income From Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -2.18 | -2.70 | -2.71 | -3.79 | -3.32+12.4% | -2.87+24.4% | -2.37+37.3% | -2.70+28.7% | -3.52+7.0% |
| Net Income Deductions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bottom Line Net Income | -2.18 | -2.70 | -2.71 | -3.79 | -3.32+12.4% | -2.87+24.4% | -2.37+37.3% | -2.70+28.7% | -3.52+7.0% |
| Eps | -$0.1700 | -$0.1600 | -$0.1500 | -$0.2100 | -$0.1700+19.0% | -$0.1300+38.1% | -$0.1300+38.1% | -$0.1300+38.1% | -$0.1300+38.1% |
| Eps Diluted | -0.17 | -0.16 | -0.15 | -0.21 | -0.17+19.0% | -0.13+38.1% | -0.13+38.1% | -0.13+38.1% | -0.13+38.1% |
| Other | |||||||||
| Filing Date | 0.002 | 0.002 | 0.002 | 0.002 | — | — | — | — | — |
| Fiscal Year | 0.002 | 0.002 | 0.002 | 0.002 | — | — | — | — | — |
| Depreciation And Amortization | 0.016 | 0.033 | 0.002 | 0.031 | 0.025-19.2% | 0.025-19.2% | 0.032+3.4% | 0.025-19.2% | 0.030-3.1% |
| Ebitda | -2.20 | -2.66 | -2.75 | -3.72 | -3.30+11.4% | -2.85+23.2% | -2.34+37.0% | -2.65+28.8% | -3.50+6.0% |
| Ebit | -2.22 | -2.69 | -2.75 | -3.75 | -3.32+11.4% | -2.88+23.2% | -2.37+36.7% | -2.67+28.8% | -3.52+6.0% |
| Weighted Average Shs Out | 13,119,588 | 16,668,513 | 17,511,908 | 18,298,309 | 19,500,000+6.6% | 21,250,000+16.1% | 18,800,000+2.7% | 20,600,000+12.6% | 22,500,000+23.0% |
| Weighted Average Shs Out Dil | 13,119,588 | 16,668,513 | 17,511,908 | 18,298,309 | 19,500,000+6.6% | 21,250,000+16.1% | 18,800,000+2.7% | 20,600,000+12.6% | 22,500,000+23.0% |